Hualan Biological Engineering, Inc.: Q1 revenue and net profit both increased, with last year's plasma collection reaching a historic high | Interpretations

① In Q1, the batch release volume of Hualan Biological Engineering, Inc.'s core blood products remains among the industry's top, and last year the company set a record high in plasma collection; ② In the vaccine business, due to seasonal factors, sales of Hualan's flu vaccine have not yet achieved large-scale growth, resulting in revenue pressure; ③ Since last year, the competition among domestic plasma stations has intensified.

cls.cnApr 27 23:40

Adding insult to injury! The core subsidiary of Shandong Sinobioway Biomedicine has been halted from production, with a revenue share of 60% | Quick read announcement.

① A subsidiary of Shandong Sinobioway Biomedicine responsible for the production and sale of interferon products has been subjected to risk control measures that involve the suspension of production and sales due to failing the Pharmaceutical GMP compliance inspection. ② Previously, Shandong Sinobioway Biomedicine's interferon α2b spray was recalled from shelves due to inspection results indicating that its "biological activity does not meet regulations."

cls.cnApr 24 23:07

The impact of U.S. tariff policy on the company is relatively small. Daan Gene Co.,Ltd.: There is currently no plan for shareholding increase | Spotlight on Earnings Conference.

① During the Earnings Conference, Daan Gene Co.,Ltd. General Manager Huang Luo stated that the current diagnostic reagent industry is experiencing both an expansion in market size and intensified market competition. ② The company indicated that since overseas revenue accounts for a small proportion, the USA's tariff increases have a limited impact on the company, but there are currently no plans for Shareholding.

cls.cnApr 10 20:32

Which Technology stocks have alpha potential under the "tariff storm"? A lengthy report from Morgan Stanley reveals the key words: AI, cloud platforms, and Cybersecurity.

The report specifically pointed out that AI/ML occupies the highest priority in the IT budget, followed closely by Cybersecurity Software, while Microsoft and Amazon continue to lead the wave of cloud migration.

Zhitong FinanceApr 9 18:43

Brokerage morning meeting highlights: The USA has increased tariffs on China, but the impact on these industries in the A-shares may be limited.

In today's brokerage morning meeting, GF SEC believes that the USA's tariffs on China have a limited impact on the A-share Computer Industry; China Securities Co.,Ltd. suggested being Bullish on the Innovative Drugs industry that is currently not affected by tariffs; Galaxy Securities stated that Deep Sea Technology has entered a new stage in Global Strategy, focusing on opportunities in core equipment.

cls.cnApr 7 08:17

The entire pharmaceutical sector has surged sharply; what happened?

On Monday, all AH Stocks in the pharmaceutical Sector surged, with innovative drugs performing the strongest. The Yinhua CSI Innovative Drugs Industry ETF collectively rose sharply, driven by three main factors: the relaxation of collective procurement, overseas license authorizations, and improvement in Earnings Reports that will reshape the Industry landscape.

wallstreetcnApr 1 20:38